Page 85 - 《中国药房》2024年7期

[20]
案，也是具有出血风险患者的首要选择 ，因此尚需更 associated thromboembolism： a randomized trial[J].
多高质量的文献来进一步验证本研究结果，为临床治疗 Chest，2022，161（3）：781-790.
提供更有价值的参考。 [11] RASKOB G E，VAN ES N，VERHAMME P，et al. Edoxa‐
参考文献 ban for the treatment of cancer-associated venous throm‐
boembolism[J]. N Engl J Med，2018，378（7）：615-624.
[ 1 ] KHORANA A A，FRANCIS C W，CULAKOVA E，et al.
[12] SCHRAG D，UNO H，ROSOVSKY R，et al. Direct oral
Thromboembolism is a leading cause of death in cancer
anticoagulants vs. low-molecular-weight heparin and recur‐
patients receiving outpatient chemotherapy[J]. J Thromb
rent VTE in patients with cancer：a randomized clinical
Haemost，2007，5（3）：632-634.
trial[J]. JAMA，2023，329（22）：1924-1933.
[ 2 ] 中国临床肿瘤学会（CSCO）肿瘤与血栓专家共识委员
[13] YOUNG A M，MARSHALL A，THIRLWALL J，et al.
会. 肿瘤相关静脉血栓栓塞症的预防与治疗中国专家指
Comparison of an oral factor Ⅹ a inhibitor with low mo‐
南：2015版[J]. 中国肿瘤临床，2015，42（20）：979-991.
lecular weight heparin in patients with cancer with venous
Consensus Committee of Cancer and Thrombosis Experts
thromboembolism： results of a randomized trial
of the Chinese Society of Clinical Oncology （CSCO）.
（SELECT-D）[J]. J Clin Oncol，2018，36（20）：2017-2023.
Prevention and treatment of tumor-associated venous
[14] GI T，KUWAHARA A，YAMASHITA A，et al. Histopatho‐
thromboembolism in China：2015 edition[J]. Chin J Clin
logical features of cancer-associated venous thromboem‐
Oncol，2015，42（20）：979-991.
bolism：presence of intrathrombus cancer cells and pro‐
[ 3 ] HEIT J A，SILVERSTEIN M D，MOHR D N，et al. Risk
thrombotic factors[J]. Arterioscler Thromb Vasc Biol，
factors for deep vein thrombosis and pulmonary embo‐
2023，43（1）：146-159.
lism：a population-based case-control study[J]. Arch Intern
[15] CHEW H K，WUN T，HARVEY D，et al. Incidence of ve‐
Med，2000，160（6）：809-815.
nous thromboembolism and its effect on survival among
[ 4 ] LEE A Y，LEVINE M N，BAKER R I，et al. Low-
patients with common cancers[J]. Arch Intern Med，2006，
molecular-weight heparin versus a coumarin for the pre‐
166（4）：458-464.
vention of recurrent venous thromboembolism in patients
[16] SØRENSEN H T，MELLEMKJAER L，OLSEN J H，et al.
with cancer[J]. N Engl J Med，2003，349（2）：146-153.
Prognosis of cancers associated with venous thromboem‐
[ 5 ] LEE A Y Y，KAMPHUISEN P W，MEYER G，et al.
bolism[J]. N Engl J Med，2000，343（25）：1846-1850.
Tinzaparin vs. warfarin for treatment of acute venous
[17] CONNOLLY S J，EIKELBOOM J，JOYNER C，et al.
thromboembolism in patients with active cancer：a ran‐
Apixaban in patients with atrial fibrillation [J]. N Engl J
domized clinical trial[J]. JAMA，2015，314（7）：677-686.
Med，2011，364（9）：806-817.
[ 6 ] HUTTEN B A，PRINS M H，GENT M，et al. Incidence of
[18] Einstein Investigators，BAUERSACHS R，BERKOWITZ
recurrent thromboembolic and bleeding complications
S D，et al. Oral rivaroxaban for sympto- matic venous
among patients with venous thromboembolism in relation
thromboembolism[J]. N Engl J Med，2010，363（26）：
to both malignancy and achieved international normalized
2499-2510.
ratio：a retrospective analysis[J]. J Clin Oncol，2000，18
[19] FRERE C，FARGE D，SCHRAG D，et al. Direct oral anti‐
（17）：3078-3083.
coagulant versus low molecular weight heparin for the
[ 7 ] AGNELLI G，BECATTINI C，MEYER G，et al. Apixaban
treatment of cancer-associated venous thromboembolism：
for the treatment of venous thromboembolism associated
2022 updated systematic review and meta-analysis of ran‐
with cancer[J]. N Engl J Med，2020，382（17）：1599-1607.
domized controlled trials[J]. J Hematol Oncol，2022，
[ 8 ] MCBANELL R D，WYSOKINSKI W E，LE-
15（1）：69.
RADEMACHER J G，et al. Apixaban and dalteparin in
[20] 马军，秦叔逵，吴一龙，等. 肿瘤相关静脉血栓栓塞症预
active malignancy-associated venous thromboembolism：
防与治疗指南：2019版[J]. 中国肿瘤临床，2019，46（13）：
the ADAM VTE trial[J]. J Thromb Haemost，2019，28
653-660.
（2）：411-421.
MA J，QIN S K，WU Y L，et al. Guidelines for prevention
[ 9 ] MOKADEM M，HASSAN A，ALGABY A Z. Efficacy
and treatment of tumor-associated venous thromboembo‐
and safety of apixaban in patients with active malignancy
lism：2019 edition[J]. Chin J Clin Oncol，2019，46（13）：
and acute deep venous thrombosis[J]. Vascular，2020，5
653-660.
（5）：745-750.
（收稿日期：2023-10-09 修回日期：2024-02-08）
[10] PLANQUETTE B， BERTOLETTI L， CHARLES-
（编辑：刘明伟）
NELSON A，et al. Rivaroxaban vs. dalteparin in cancer-
中国药房 2024年第35卷第7期 China Pharmacy 2024 Vol. 35 No. 7 · 847 ·